Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that for the nine months completed March 31, 2015, the revenues came at $64,024 against revenue of $250,859 for the same period, a year earlier. The sales for both periods comprised of timber from the tea estate operations in South Africa.
The cost of sales for the first three quarters completed March 31, 2015 stood at $583,506 compared to $483,675 in the comparable period, a year ago. The cost of sales increased by $99,831, which can be attributed to expenses incurred with operating the factory and managing the Senteeko Tea Estate.
Metabolix, Inc. (NASDAQ:MBLX) Reports Quarterly Numbers
Metabolix, Inc. (NASDAQ:MBLX) disclosed that net loss from continuing operations declined to of $6.1 million in 2Q2015 from $6.8 million in the same period, a year ago. Joseph Shaulson, the President and CEO stated that in June, the company closed a private placement to obtain $15 million in capital. These funds will be used to implement strategic business plans with a prime focus on executing commercial plans to increase Mirel specialty biopolymers sales.
The CEO said that Metabolix have completed the underway capital expansion of its pilot recovery center. Also, they have initiated biopolymer recovery measures with fermentation broth made earlier this year. In the third quarter, they intend to ramp up the production to new nameplate capacity in support with new U.S. supplier.
CTI Industries Corp. (NASDAQ:CTIB) Reports Quarterly Numbers
CTI Industries Corp. (NASDAQ:CTIB) announced that net income in 2Q2015 was $52,000 against a net loss of $122,000 in the same quarter, a year ago. For 1H2015, the net Income was $336,000 compared to a net loss of $77,000 in the same quarter, last year. The EBITDA jumped 62% to $918,000 in 2Q2015 from $568,000 in 2Q2014.
In early morning trade on Thursday, the stock price of Plandai declined over 1% and is trading close to $0.143.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: